Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8574987 | 0.85 | CYP11B1 (0.33) | CYP11B1CYP11B2TRPV4MAOAMAOB | |
| SCHEMBL21811729 | 0.80 | TRPV4 (0.39) | CYP11B1CYP11B2TRPV4 | |
| SCHEMBL9447055 | 0.77 | TRPV4 (0.39) | CYP11B1CYP11B2TRPV4MAOAMAOB | |
| SCHEMBL8576407 | 0.76 | TDP1 (0.36) | TRPV4 | |
| SCHEMBL21811583 | 0.75 | PGR (0.33) | CYP11B1CYP11B2MAOAMAOB | |
| SCHEMBL30950508 | 0.74 | DYRK1A (0.41) | — | |
| SCHEMBL16122475 | 0.74 | TRPV4 (0.36) | CYP11B1CYP11B2TRPV4MAOAMAOB | |
| SCHEMBL17711239 | 0.74 | — | — | |
| SCHEMBL24128013 | 0.73 | TRPV4 (0.37) | CYP11B1CYP11B2TRPV4MAOAMAOB | |
| SCHEMBL21811549 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12171741-B2 | 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors | NIKANG THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20220054451-A1 | 2,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-20220054451-A1 | 2,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3849541-A1 | 2,3-DIHYDROBENZO[B]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | Nikang Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020055883-A1 | 2,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054451-A1 | 2,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | HIF1AN, HIF1A, EGLN2 | CYP11B1 539/4885CYP11B2 166/4885TRPV4 3778/4885 |
| US-12171741-B2 | 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors | HIF1AN, HIF1A, EGLN2 | CYP11B1 539/4885CYP11B2 166/4885TRPV4 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.